Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

SCLC,Extensive Stage: early-phase trial registry

1 of 1 indexed SCLC,Extensive Stage trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

SCLC,Extensive Stage: 1 US clinical trial tracked, 1 recruiting.

SCLC,Extensive Stage is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is RayzeBio, running 1 of these trials.

Enrollment posture brief

Registry condition sclcextensive-stage

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

SCLC,Extensive Stage (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near SCLC,Extensive Stage

SCLC,Extensive Stage lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for SCLC,Extensive Stage on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. SCLC,Extensive Stage is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

RayzeBio 1 trials

Named interventions

Most-linked intervention names on SCLC,Extensive Stage records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

RYZ101 Dose Level -1 Drug
1 trials
RYZ101 Dose Level 3 Drug
1 trials
RYZ101 Dose Level 2 Drug
1 trials
RYZ101 Dose Level 1 Drug
1 trials
Atezolizumab Drug
1 trials

US sites by state

Facility locations filed on SCLC,Extensive Stage trials. A trial with sites in several states counts in each.

Utah 1 trials
Texas 1 trials
Puerto Rico 1 trials
Nebraska 1 trials
Missouri 1 trials
Minnesota 1 trials
Michigan 1 trials
Kentucky 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this SCLC,Extensive Stage page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 SCLC,Extensive Stage trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • RayzeBio sponsors the most SCLC,Extensive Stage trials on record, review their full trial history before evaluating a specific study. See RayzeBio's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This SCLC,Extensive Stage condition card totals 1 registered trials; most-linked intervention RYZ101 Dose Level -1; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.